Caroline Piatek

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Austin Kulasekararaj, Anita Hill, Scott T. Rottinghaus et al. · Blood · 2018 · 378 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

John Devin Peipert, Austin Kulasekararaj, Anna Gayà et al. · PLoS ONE · 2020 · 48 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Genetic Screens for Enhancers of <i>brahma</i> Reveal Functional Interactions Between the BRM Chromatin-Remodeling Complex and the Delta-Notch Signal Transduction Pathway in Drosophila

Jennifer A. Armstrong, Adam S. Sperling, Renate Deuring et al. · Genetics · 2005 · 40 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Austin Kulasekararaj, Anita Hill, Saskia Langemeijer et al. · European Journal Of Haematology · 2020 · 36 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, <scp>double‐blind</scp>, <scp>placebo‐controlled</scp>, global study (<scp>FORWARD</scp>)

David J. Kuter, Caroline Piatek, Alexander Röth et al. · American Journal of Hematology · 2023 · 34 citations · Full text

Medicine, Hematology, Pharmacotherapy +14